Research Article
Bioinorganic Preparation of Hydroxyapatite and Rare Earth Substituted Hydroxyapatite for Biomaterials Applications
Table 3
Inhibition zone (mean ± standard deviation) of gentamicin/nystatin, HA, and Nd-Ce/HA.
| | Type of microorganism | Gentamicin/nystatin | HA | Nd-Ce/HA | | Mean ± SD (mm) | Sample number | Mean ± SD (mm) | Sample number | Mean ± SD (mm) | Sample number |
| | E. coli | 17.37 ± 0.23 | 3 | 13.97 ± 0.15 | 3 | 17.60 ± 0.38 | 3 | | S. aureus | 16.60 ± 0.31 | 3 | 14.90 ± 0.26 | 3 | 13.97 ± 0.15 | 3 | | S. mutans | 9.90 ± 0.21 | 3 | 13.53 ± 0.27 | 3 | 12.13 ± 0.19 | 3 | | S. epidermidis | 13.10 ± 0.06 | 3 | 12.13 ± 0.09 | 3 | 13.17 ± 0.17 | 3 | | C. albicans | 18.07 ± 0.46 | 3 | 26.77 ± 0.46 | 3 | 22.17 ± 0.12 | 3 |
|
|
